Your browser is no longer supported. Please, upgrade your browser.
Synlogic, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own0.70% Shs Outstand37.82M Perf Week2.10%
Market Cap125.29M Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float32.76M Perf Month-18.66%
Income-59.20M PEG- EPS next Q-0.39 Inst Own36.90% Short Float1.28% Perf Quarter4.29%
Sales0.50M P/S250.58 EPS this Y2.70% Inst Trans5.88% Short Ratio0.92 Perf Half Y66.67%
Book/sh3.04 P/B1.12 EPS next Y12.70% ROA-38.00% Target Price- Perf Year81.82%
Cash/sh2.72 P/C1.25 EPS next 5Y- ROE-46.50% 52W Range1.78 - 5.11 Perf YTD57.41%
Dividend- P/FCF- EPS past 5Y30.00% ROI-52.50% 52W High-33.46% Beta1.94
Dividend %- Quick Ratio12.90 Sales past 5Y- Gross Margin- 52W Low91.01% ATR0.33
Employees72 Current Ratio12.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)45.30 Volatility7.05% 10.91%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.30% Profit Margin- Rel Volume4.35 Prev Close3.16
ShortableYes LT Debt/Eq0.00 EarningsMar 25 BMO Payout- Avg Volume453.36K Price3.40
Recom1.70 SMA20-6.59% SMA50-13.59% SMA20025.03% Volume1,971,481 Change7.59%
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Apr-16-21 06:00AM  
Apr-15-21 04:02PM  
Apr-13-21 09:20AM  
Apr-10-21 09:37AM  
Apr-01-21 03:33PM  
Mar-26-21 05:16AM  
Mar-25-21 07:58AM  
Mar-24-21 04:05PM  
Mar-16-21 02:44PM  
Mar-15-21 09:55AM  
Mar-08-21 07:00AM  
Feb-15-21 07:00AM  
Feb-10-21 07:00AM  
Feb-02-21 06:30AM  
Jan-14-21 08:56AM  
Jan-11-21 06:30AM  
Dec-14-20 11:41AM  
Dec-09-20 06:30AM  
Dec-07-20 12:27PM  
Dec-02-20 10:47PM  
Nov-27-20 08:47AM  
Nov-18-20 06:30AM  
Nov-09-20 10:04AM  
Nov-05-20 08:42AM  
Nov-04-20 04:05PM  
Oct-27-20 06:30AM  
Oct-22-20 06:30AM  
Sep-14-20 07:00AM  
Sep-10-20 02:15PM  
Sep-08-20 11:46AM  
Aug-28-20 09:37AM  
Aug-24-20 03:30PM  
Aug-06-20 07:00AM  
Jul-31-20 02:49PM  
Jul-30-20 07:00AM  
Jul-28-20 07:30AM  
Jun-17-20 09:38PM  
Jun-12-20 11:19AM  
Jun-01-20 05:46AM  
May-27-20 08:00AM  
May-21-20 04:02PM  
May-08-20 07:44AM  
May-04-20 04:02PM  
Apr-01-20 07:32AM  
Mar-30-20 06:00AM  
Mar-15-20 11:00AM  
Mar-12-20 04:19PM  
Mar-11-20 04:02PM  
Mar-05-20 04:02PM  
Feb-19-20 02:04PM  
Feb-18-20 04:02PM  
Jan-24-20 08:01AM  
Jan-14-20 08:33AM  
Jan-09-20 06:00AM  
Jan-06-20 09:20AM  
Dec-20-19 03:29PM  
Dec-12-19 07:55AM  
Dec-11-19 06:00AM  
Dec-10-19 07:00AM  
Dec-05-19 02:37PM  
Nov-25-19 04:02PM  
Nov-14-19 11:41AM  
Nov-12-19 04:02PM  
Nov-07-19 03:07PM  
Nov-05-19 04:02PM  
Sep-30-19 04:02PM  
Sep-26-19 07:00AM  
Sep-25-19 05:23PM  
Sep-12-19 12:56PM  
Sep-06-19 03:46PM  
Sep-05-19 08:12AM  
Sep-04-19 04:01PM  
Aug-24-19 01:46PM  
Aug-21-19 06:03PM  
Aug-20-19 07:38AM  
Aug-08-19 05:00PM  
Aug-01-19 04:02PM  
Jul-25-19 09:54AM  
Jul-15-19 06:00AM  
Jul-01-19 01:10PM  
Jun-12-19 06:30AM  
May-23-19 04:15PM  
May-22-19 07:00AM  
May-16-19 09:14PM  
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.